New drug combo aims to control metastatic breast cancer
NCT ID NCT02942355
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tests whether combining anastrozole and palbociclib can safely control hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women. About 40 participants will receive the drugs either as their first treatment or after initial chemotherapy. The goal is to see if this approach can delay cancer progression and manage side effects like low white blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.